Abstract: AIM: To validate the relationship between the release kinetics of serum creatine kinase isoenzyme MB (CK-MB) and cardiac tropnin I (cTnI) and myocardial microvascular impairment during the development of no-reflow phenomenon by measurement of serum CK-MB and cTnI in combination with administration of Albunex. METHODS: 19 dogs underwent 60 min myocardial ischemia, followed by reperfusion of 60 min (n=6), 120 min (n=6) and 180 min (n=7), respectively.Myocardial contrast echocardiography (MCE) was performed by a bolus injection of Albunex.The measurement of peripheral blood concentrations of CK-MB and cTnI at baseline, 60 min ischemia (T0) and 60 min reperfusion (T60) were initiated, and then the increase slope (T60-T0 60) and relative increase value (T60-T0/T0) were calculated at 60 min reperfusion. RESULTS: The concentrations of serum CK-MB and cTnI were markedly higher at 60 min myocardial ischemia than those at baseline (P <0.01).At 60 min reperfusion, a significant difference in the levels of CK-MB and cTnI was observed between ref low group and no-reflow group (P < 0.01).There was a marked difference in the levels of CK-MB and cTnI between reflow group and no-reflow group, too (P <0.01).An extremely significant difference in the increase slope and relative increase value at 60 min reperfusion between two groups was found (P < 0.001). CONCLUSION: These findings show that damaged microvarculature may profoundly influence the release kinetics of serum CK-MB and cTnI.

Key words: Albunex, no-reflow phenomenon, release kinetics, creatine kinase isoenzyme MB, cardiac tropnin I